<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763385</url>
  </required_header>
  <id_info>
    <org_study_id>2012-75-634</org_study_id>
    <nct_id>NCT01763385</nct_id>
  </id_info>
  <brief_title>Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases</brief_title>
  <acronym>TRACTS</acronym>
  <official_title>Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases: A Prospective Multicenter Trial(TRACTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wu Jieping Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Armed Police Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wu Jieping Medical Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is aim to explore non-increased-intracranial-pressure symptomatic brain
      metastases of NSCLC, and if the OS of secondary brain radiotherapy after recurrence with
      Erlotinib is better than Erlotinib with concurrent brain radiotherapy. Treatment group are
      treated with Erlotinib until brain tumor progression, then gave brain radiotherapy, and
      continued to take Erlotinib till extracranial lesions progression. Control group are
      Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after
      radiotherapy until recurrence or termination for other reasons.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3.5year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Erlotinib &amp; secondary brain radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib &amp; concurrent brain radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <arm_group_label>Erlotinib &amp; secondary brain radiotherapy</arm_group_label>
    <arm_group_label>Erlotinib &amp; concurrent brain radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>concurrent brain radiotherapy</intervention_name>
    <arm_group_label>Erlotinib &amp; concurrent brain radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>secondary brain radiotherapy</intervention_name>
    <arm_group_label>Erlotinib &amp; secondary brain radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over the age of 18 years old;

          2. Tissue or cell pathological diagnosis of NSCLC;

          3. Brain CT or MR validated BM;

          4. Non-increased-intracranial-pressure symptomatic BM;

          5. Haven't received TKI target treatment;

          6. Haven't received brain radiotherapy;

          7. Patients in initial treatment should be detected EGFR mutation;

          8. Expected survival more than 6 months;

          9. KPS no less than 70, or KPS less than 70 caused by paralysis due to recent brain
             metastases;

         10. Liver and kidney function requirements: SGOT/SGPT≦2.5 times of the upper limit, Total
             bilirubin≦1.5 times of the upper limit, serum Creatinine≦1.5 times of the upper limit;

         11. Routine blood test requirements: WBC≧3.0×109/L, NE≧1.8×109/L, PLT≧90×109/L，no
             requirement for Hb;

         12. Blood glucose requirements: within the normal range, diabetic patients are receiving
             treatment and their glucose was being controlled in a steady state;

         13. Female patients in childbearing age: HCG (-);

         14. Patients signed an inform Consent.

        Exclusion Criteria:

          1. Those with Erlotinib drug allergies;

          2. Those with mathematical understanding of the most simple life questions, such as
             &quot;walking&quot;, those difficult for doctors to communicate;

          3. Those without guardians or families;

          4. Those with abnormal routine blood test, liver and kidney function, and blood glucose
             beyond the above boundaries and difficult to correcting for more than 2 weeks;

          5. Those with any unstable medical status (including active infection, uncontrolled
             hypertension, unstable angina, congestive heart failure, myocardial infarction (within
             one year before treatment initiation), and severe arrhythmia, liver, kidney or
             metabolic disease requiring drug therapy);

          6. Those with any other disease, neurological or metabolic dysfunction, and physical
             examination or laboratory test results showed that the study drugs may increase the
             risk of treatment-related complications;

          7. Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huanjun Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huanjun Yang, Master</last_name>
    <phone>+86-21-64175590</phone>
    <phone_ext>6723</phone_ext>
    <email>yanghj_1@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huanjun Yang, Master</last_name>
      <phone>+86-21-64175590</phone>
      <phone_ext>6723</phone_ext>
      <email>yanghj_1@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <last_update_submitted>December 22, 2014</last_update_submitted>
  <last_update_submitted_qc>December 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Yang Huan Jun</investigator_full_name>
    <investigator_title>Fudan University</investigator_title>
  </responsible_party>
  <keyword>Erlotinib</keyword>
  <keyword>brain radiotherapy</keyword>
  <keyword>NSCLC</keyword>
  <keyword>brain metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

